Back to discover

Protein / target

Mucin-5B

Encoded byMUC5BQ9HC84Homo sapiensSwiss-Prot
Antibody-tractable
Druggability
GO CC high conf
1
Research papers

Protein at a glance

Biological role

Extracellular matrix structural constituent

Strongest disease association

Lung Diseases, Interstitial

Via encoding gene MUC5B · Genetic evidence · score 0.73

Research activity

Emerging research

1 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Gel-forming mucin that is thought to contribute to the lubricating and viscoelastic properties of whole saliva and cervical mucus

Subcellular location

Secreted
Domains and Gene Ontology detail (19)

Domains & features

VWFD 1TIL 1VWFD 2TIL 2TIL 3VWFC 1VWFD 3VWFD 4VWFC 2VWFC 3CTCK

Gene Ontology

  • Cextracellular exosome
  • Cextracellular matrix
  • Cextracellular space
  • CGolgi lumen
  • Cplasma membrane
  • Fextracellular matrix structural constituent
  • Fmetal ion binding
  • Pnegative regulation of single-species biofilm formation in or on host organism

5762 aa · 596 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell adhesionGO
View supporting evidence

Cell adhesion

  • ·extracellular matrix
  • ·extracellular matrix structural constituent

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene MUC5B

Gene-level evidence surfaced through the gene MUC5Bthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Idiopathic Pulmonary Fibrosis
0.78Well supported

Genetic evidence dominant · Open Targets 0.60

Lung Diseases, Interstitial
0.77Well supported

Genetic evidence dominant · Open Targets 0.55

COVID-19
0.74Moderately supported

Genetic evidence dominant · Open Targets 0.45

Respiratory Tract Diseases
0.72Moderately supported

Genetic evidence dominant · Open Targets 0.44

Respiratory Insufficiency
0.71Moderately supported

Genetic evidence dominant · Open Targets 0.43

View evidence synthesis (5)
Idiopathic Pulmonary FibrosisWell supported
0.78
agreement 0.660.89
Genetic74%Literature15%Animal model11%RNA expression0%Genetic literaturedup

Open Targets aggregate 0.60 · 4 independent evidence families · 1 not counted as duplicate

Lung Diseases, InterstitialWell supported
0.77
agreement 0.630.91
Genetic84%Literature16%Genetic literaturedup

Open Targets aggregate 0.55 · 2 independent evidence families · 1 not counted as duplicate

COVID-19Moderately supported
0.74
agreement 0.600.88
Genetic87%Literature14%

Open Targets aggregate 0.45 · 2 independent evidence families

Respiratory Tract DiseasesModerately supported
0.72
agreement 0.580.86
Genetic98%Literature3%

Open Targets aggregate 0.44 · 2 independent evidence families

Respiratory InsufficiencyModerately supported
0.71
agreement 0.570.85
Genetic98%Literature2%

Open Targets aggregate 0.43 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Idiopathic Pulmonary Fibrosis0.60
Lung Diseases, Interstitial0.55
Pulmonary Fibrosis0.47
COVID-190.45
Respiratory Tract Diseases0.44
Respiratory Insufficiency0.43
Chronic lung disease0.41

Tractability

AntibodiesEmerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (3)
AB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMM

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Adegunsoye A · American journal of respiratory and critical care medicine · 2024

Recent

Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine.

Adegunsoye A · American journal of respiratory and critical care medicine · 2024

Europe PMC papers linked directly to this protein.

Related family literature

7

Papers about “Mucins” — a broader family this protein belongs to. Shown as context; not counted as papers specifically about this protein.

Mucus Structure, Viscoelastic Properties, and Composition in Chronic Respiratory Diseases.

Abrami M · International journal of molecular sciences · 2024

via Mucins

MUC1 and MUC16: critical for immune modulation in cancer therapeutics.

Chen X · Frontiers in immunology · 2024

via Mucins

Mucins and the Microbiome.

Hansson GC · Annual review of biochemistry · 2020

via Mucins

Intestinal goblet cells and mucins in health and disease: recent insights and progress.

Kim YS · Current gastroenterology reports · 2010

via Mucins

Europe PMC literature, reached through curated HGNC family membership. Membership is a taxonomic relationship — it does not imply this protein participates in every mechanism these papers discuss.